Emerging Technologies Audited

business-4.png

Cell and gene therapies and antibody drug conjugates are seen as the next frontiers in medicine. With our comprehensive offering that spans genetically and virally modified cell and gene therapies, viral vector gene therapies and antibody drug conjugates (ADCs), Lonza is at the forefront of these emerging industries.

Lonza, with our decades of experience in cell processing, is an industry leader in process development and manufacturing of cells under current good manufacturing practices (cGMP) for both allogeneic and autologous cell-based therapies. Our broad service offerings – combined with a global footprint that spans the United States, Europe and Asia – enable us to support our clients throughout clinical development and commercial production.

At our new Houston, TX (USA), facility, scheduled to be completed in Q1 2018, the Lonza team offers development and cGMP services for cell and gene therapies, including viral vector production. The range includes a wide selection of product types such as adenoviral, adeno-associated virus (AAV) and lentiviral vectors.

Our bioconjugate team in Visp (CH) is one of the industry leaders in process development and cGMP manufacturing of clinical and commercial bioconjugates, including ADCs. The team's track record encompasses several bioconjugate constructs, as well as novel payload, linker and conjugation technologies. A reorganization of the Emerging Technologies business unit in late 2017 focused our efforts in the fast-growing field of cell and gene therapies and ensured our bioconjugation services were fully aligned with our offerings in mammalian development and clinical manufacturing services.


Discover More

Highlights 2017
Innovation & Initiatives

For additional information about our services, such as process development, cGMP manufacturing, assay development, analytical and all other related services, click on our websites below:

See our facilities on our 360° virtual tour.